Harmony Biosciences Holdings, Inc. (HRMY)
NASDAQ: HRMY · IEX Real-Time Price · USD
32.25
+0.21 (0.66%)
Jul 22, 2024, 10:12 AM EDT - Market open

HRMY Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Year Ending
TTM Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019 2018
Net Income
137.7128.85181.4734.6-63.85-187.21
Upgrade
Depreciation & Amortization
24.4224.3623.3918.8410.243.21
Upgrade
Share-Based Compensation
35.0831.2126.9116.115.199.91
Upgrade
Other Operating Activities
10.7734.97-87.2929.0218.5363.42
Upgrade
Operating Cash Flow
207.97219.39144.4798.56-2.99-75.44
Upgrade
Operating Cash Flow Growth
31.48%51.86%46.58%---
Upgrade
Capital Expenditures
-0.32-0.31-0.17-0.3-0-0.15
Upgrade
Acquisitions
-36.97-36.97-40-100-2-127
Upgrade
Change in Investments
-13.55-9.16-101.66000
Upgrade
Investing Cash Flow
-50.84-46.44-141.83-100.3-2-127.15
Upgrade
Share Issuance / Repurchase
-98.74-94.958.8439.07147.760.09
Upgrade
Debt Issued / Paid
-13.34-10.09-2-31.6573.6194.82
Upgrade
Other Financing Activities
-0.51-0.51---12.2148.87
Upgrade
Financing Cash Flow
-112.6-105.556.847.42209.16143.77
Upgrade
Net Cash Flow
44.5467.49.485.68204.17-58.82
Upgrade
Free Cash Flow
207.65219.08144.2998.26-2.99-75.59
Upgrade
Free Cash Flow Growth
31.39%51.83%46.85%---
Upgrade
Free Cash Flow Margin
33.63%37.64%32.95%32.17%-1.87%-1260.80%
Upgrade
Free Cash Flow Per Share
3.663.682.441.71-0.12-9.72
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).